187597-18-8

Basic information

• Product Name: 1-(6-METHYL[1,3]THIAZOLO[3,2-B][1,2,4]TRIAZOL-5-YL)-1-ETHANONE
• Synonyms: 1-(6-METHYL-1H-7LAMBDA5-[1,3]THIAZOLO[2,3-E][1,2,4]TRIAZOL-5-YL)-1-ETHANONE;1-(6-METHYL[1,3]THIAZOLO[3,2-B][1,2,4]TRIAZOL-5-YL)-1-ETHANONE
• CAS NO: 187597-18-8
• Molecular Formula: C7H7N3OS
• Molecular Weight: 181.21
• Mol File: 187597-18-8.mol
• Article Data: 3

Chemical Properties

• Melting Point: 147-149°C
• Appearance: /
• CAS DataBase Reference: 1-(6-METHYL[1,3]THIAZOLO[3,2-B][1,2,4]TRIAZOL-5-YL)-1-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-METHYL[1,3]THIAZOLO[3,2-B][1,2,4]TRIAZOL-5-YL)-1-ETHANONE(187597-18-8)
• EPA Substance Registry System: 1-(6-METHYL[1,3]THIAZOLO[3,2-B][1,2,4]TRIAZOL-5-YL)-1-ETHANONE(187597-18-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 187597-18-8(Hazardous Substances Data)

Usage

Uses

1-{6-Methyl-[1,2,4]triazolo[3,2-b][1,3]thiazol-5-yl}ethan-1-one can be used to identify novel orally active mGluR5 antagonist GSK2210875.

Upstream product

• 3179-31-5 2,3-dihydro-1H-1,2,4-triazole-3-thione 
• 1694-29-7 3-chloropentane-2,4-dione 
• 3179-31-5 2,4-dihydro-[1,2,4]triazole-3-thione 

Downstream Products

• 871122-21-3 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-ethan-1-one oxime 
• 871122-21-3 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-ethan-1-one oxime 
• 871122-21-3 1-(6-methylthiazolo[3,2-b][1,2,4]triazol-5-yl)-ethan-1-one oxime 

Relevant articles and documents

Synthesis of New Thiazolo[3,2-b][1,2,4]triazole Derivatives and Preliminary Evaluation of Their Biological Activity

Heterocyclization of 3-[(1H-1,2,4-triazol-3-yl)thio]pentane-2,4-dione afforded 1-(6-methylthiazolo[3,2-b][1,2,4]-triazol-5-yl)ethan-1-one, the reactions of which with hydroxylamine, hydrazincarboxamide, hydrazincarbothioamide, hydrazine hydrate and para-t

USE OF THIAZOLOIMIDAZOLES, THIAZOLOTETRAZOLES AND THIAZOLOTRIAZOLES AS MGLUR5 ANTAGONISTS

The invention relates to the use of thiazolotriazole, thiazoloimidazole and thiazolotetrazole derivatives of formula (I) in treating diseases and conditions for which antagonism of the mGluR5 receptor is beneficial, in particular substance related disorders. The invention also relates to certain novel derivatives. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.